Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening

Omabe, Maxwell; Omabe, Kenneth Nwobini; Clement, Famurewa Ademola; Omabe, Grace Maxwell

doi:10.2174/1871530316666160201145934

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A specific characteristic of PCOS, independent of obesity, is IR and increased gluconeogenesis [18]. Latest researches regarding the metabolites related to glucose [13][14][15][16]17].…”

Section: Metabolites Related To Glucose Metabolismmentioning

confidence: 99%

Metabolic Analysis in Women with Polycystic Ovary Highlight Specific Biomarkers of Insulin Resistance

Vonica¹,

Fodor²,

Román³

et al. 2019

Rev. Chim.

View full text Add to dashboard Cite

The aim of the paper is to detect insulin resistance (IR) biomarkers via metabolomics. It is important to understand the PCOS pathophysiology, diagnosis measures and, subsequently, to improve treatment type and time of IR in PCOS. In most cases, almost half of the women with PCOS have IR which is triggered by inflammation, glucotoxicity and lipotoxicity. In this work was conducted a systematic review of all the papers that used metabolomics for detecting IR biomarkers in PCOS women. The exclusion criteria were: reviews, study population with women bellow 18 years of age, studies including animals and articles not in English, remaining 4 records. The results from the literature shown that phosphatidylcholines were decreased in IR PCOS women when compared to controls. Nonetheless, trans-2-hexenoylcoa, linoleic acid, leucine, myristic acid and palmitic acid regarding lipid metabolism and tyrosine, lysine, phenylalanine a-aminoadipic acid regarding amino acid metabolism were also corelated to IR in PCOS women when compared with healthy or IR controls. Lactate was the only increased metabolite related to glucose metabolism in IR PCOS women. Metabolic alteration in PCOS women with IR when are compared with controls and results that those are brought by both PCOS and IR. Lyso-phosphatidylcholine have an important pro-inflammatory and altered insulin signaling effect, both alterations being considered hallmarks of PCOS women. Serine hyperphosphorylation of the receptor accentuates IR by decreasing the signaling of insulin receptor. Moreover, high levels of lactate correlated with IR in PCOS women may indicate high muscle glycolysis, hepatic glucose production and peripheral glucose uptake. IR biomarkers in PCOS women were evidenced by metabolomics technique.

show abstract

“…A specific characteristic of PCOS, independent of obesity, is IR and increased gluconeogenesis [18]. Latest researches regarding the metabolites related to glucose [13][14][15][16]17].…”

Section: Metabolites Related To Glucose Metabolismmentioning

confidence: 99%

Metabolic Analysis in Women with Polycystic Ovary Highlight Specific Biomarkers of Insulin Resistance

Vonica¹,

Fodor²,

Román³

et al. 2019

Rev. Chim.

View full text Add to dashboard Cite

show abstract

Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS)

Jiang

Chen

et al. 2017

Clinica Chimica Acta

View full text Add to dashboard Cite

Preparation of Metformin/Doxorubicin-Bovine Serum Albumin-Hyaluronic Acid-Carbon Dots Nanoparticles and Their Application in Treating Polycystic Ovary Syndrome on Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor of Patient Combine with Metformin

Cheng

Jiang

et al. 2021

sci adv mater

View full text Add to dashboard Cite

At present, carbon dot nanoparticle has good light stability and bioavailability, which has become a novel type of nano material widely employed in medicine. This investigation aimed to study the effects of nanomedicine based on Metformin/doxorubicin-bovine serum albumin-hyaluronic acid-carbon dots (Met/DOX-BSA-HA-CD) on matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) of polycystic ovarian syndrome (PCOS) patients. First, Met/DOX-BSA-HA-CD was prepared from Met and doxorubicin (DOX) and BSA-HACD solution. 30 PCOS patients accepted by hospital were deemed as experimental group, and 30 healthy married women were taken as controls. Met/DOX-BSA-HA-CD nanomedicine was prepared and applied to the treatment of 30 PCOS patients. The results showed that the average particle size of Met/DOX-BSA-HA-CD was about 120 nm. MMP-9 immunohistochemical H-Score (285.32±36.41 points) of the endometrial glandular epithelium of experimental group was considerably inferior to controls (364.35±26.74 points) (P < 0.05). VEGF level of experimental group (103.25±20.64 pg/mL) was substantially superior to controls (86.32±14.21 pg/mL) (P < 0.05). Moreover, serum VEGF level was positively correlated with body mass index (r = 0.236, P < 0.05), and negatively correlated with follicle stimulating hormone/luteinizing hormone (FSH/LH) (r =−0.061, P < 0.05). The carbon dots prepared in this study had good light stability. The ratio of nanocarrier to drug: bovine serum albumin-hyaluronic acid-carbon dots:metformin = 4:1 was determined as the feeding ratio, and the embedding rate was 39.8%. The expression of MMP-9 in the endometrial glandular epithelium of PCOS patients was expected to be an indicator of endometrial receptivity. PCOS patients had endocrine disorders and abnormal VEGF levels.

show abstract

Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening

Abstract: Indeed, emerging evidence points that the severity of menstrual problems could serve as a predictor of the like-hood of insulin resistance in women of reproductive age, suggesting the need for routine metabolic screening and early intervention in PCOS.

Cited by 3 publications

References 0 publications

Metabolic Analysis in Women with Polycystic Ovary Highlight Specific Biomarkers of Insulin Resistance

Metabolic Analysis in Women with Polycystic Ovary Highlight Specific Biomarkers of Insulin Resistance

Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS)

Preparation of Metformin/Doxorubicin-Bovine Serum Albumin-Hyaluronic Acid-Carbon Dots Nanoparticles and Their Application in Treating Polycystic Ovary Syndrome on Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor of Patient Combine with Metformin

Contact Info

Product

Resources

About